Links between genetic and environmental factors and prostate cancer risk
Peter Ekman,
Henrik Grönberg,
Hideyasu Matsuyama,
Merja Kivineva,
Ulf S.R. Bergerheim,
Chunde Li,
Corresponding Author
Peter Ekman
Department of Urology, Karolinska Hospital, Stockholm, Sweden
Department of Urology, Karolinska Hospital, S-171 76 Stockholm, SwedenSearch for more papers by this authorHenrik Grönberg
Department of Oncology, Umeå University Hospital, Umeå, Sweden
Search for more papers by this authorHideyasu Matsuyama
Department of Urology, Yamaguchi Red Cross Hospital, Yamaguchi, Japan
Search for more papers by this authorMerja Kivineva
Department of Anatomy, Medical School, University of Tampere, Tampere, Finland
Search for more papers by this authorUlf S.R. Bergerheim
Department of Urology, Karolinska Hospital, Stockholm, Sweden
Search for more papers by this authorChunde Li
Department of Urology, Karolinska Hospital, Stockholm, Sweden
Search for more papers by this authorPeter Ekman,
Henrik Grönberg,
Hideyasu Matsuyama,
Merja Kivineva,
Ulf S.R. Bergerheim,
Chunde Li,
Corresponding Author
Peter Ekman
Department of Urology, Karolinska Hospital, Stockholm, Sweden
Department of Urology, Karolinska Hospital, S-171 76 Stockholm, SwedenSearch for more papers by this authorHenrik Grönberg
Department of Oncology, Umeå University Hospital, Umeå, Sweden
Search for more papers by this authorHideyasu Matsuyama
Department of Urology, Yamaguchi Red Cross Hospital, Yamaguchi, Japan
Search for more papers by this authorMerja Kivineva
Department of Anatomy, Medical School, University of Tampere, Tampere, Finland
Search for more papers by this authorUlf S.R. Bergerheim
Department of Urology, Karolinska Hospital, Stockholm, Sweden
Search for more papers by this authorChunde Li
Department of Urology, Karolinska Hospital, Stockholm, Sweden
Search for more papers by this authorFirst published: 05 May 1999
Citations: 30
Abstract
BACKGROUND
Genetic polymorphisms and expression of steroid receptors may explain why some individuals are more at risk of developing prostate cancer. Some risk factors often discussed are androgen stimulation, and vitamin A and D deficiency. Long CAG-repeats in exon 1 of the androgen receptor (AR) gene on the X chromosome seem to have a protective role against androgen overstimulation. Likewise, long vitamin D receptor alleles in the poly-A tract may prevent vitamin D stimulation.
METHODS
Blood samples from 59 Swedish patients with sporadic prostate cancers, 59 with hereditary prostate cancer, and 34 Japanese prostate cancer patients were compared with benign controls. Tissue specimens from 37 Swedish and 23 Japanese prostate cancer patients with matching blood samples were investigated by immunohistochemical techniques.
RESULTS
The number of CAG-repeats was identical in sporadic and hereditary prostate cancer patients, but the repeats were significantly shorter than in benign controls. Benign Japanese controls were similar to Swedish controls, but Japanese prostate cancers had longer repeats than did controls. Both the vitamin D and A receptor staining was stronger in Japanese than in Swedish prostate cancer specimens. Prostate cancer occurs approximately 5 years later in Japanese compared with Swedish men.
CONCLUSIONS
Varying lengths of CAG-repeats of the androgen receptor cannot fully explain racial differences in clinical prostate cancer incidence. A larger content of vitamin A and D receptors may be linked to a delayed onset of clinical prostate cancer in Japanese men. Prostate 39:262–268, 1999. © 1999 Wiley-Liss, Inc.
REFERENCES
- 1Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371–1374. Medline
- 2Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J, Grönberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998; 20: 175–179. Medline
- 3Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143: 742–746. Medline
- 4Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805–810. Medline
- 5Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 25: 467–472.
- 6Kivineva M, Bläuer M, Syvälä H, Tammela T, Tuohimaa P. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 1998; 66: 121–127. Medline
- 7Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166–170. Medline
- 8Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861–2869.
Medline
10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G PubMed Web of Science® Google Scholar
- 9Miller AB, Howe GR, Jain M, Craib KJ, Harrison L. Food items and food groups as risk factors in a case-control study of diet and colorectal cancer. Int J Cancer 1983; 32: 155–161. Medline
- 10Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 442–447. Medline
- 11Zhuang Y-H, Ylikomi T, Lindfors M, Piippo S, Tuohimaa P. Immunolocalization of retinoic acid receptors in rat, mouse and human ovary and uterus. J Steroid Biochem Mol Biol 1994; 48: 61–68. Medline
- 12Rousseau EJ, Davison AJ, Dunn B. Protection by beta-carotene and related compounds against oxygen-mediated cytotoxicity and genotoxicity: implications for carcinogenesis and anticarcinogenesis. Free Radic Biol Med 1992; 13: 407–433. Medline
- 13Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989; 274: 532–538. Medline
- 14Ascherio A, Stampfer MJ, Colditz GA, Rimm EB, Litin L, Willett WC. Correlations of vitamin A and E intakes with the plasma concentrations of carotenoids and tocopherols among American men and women. J Nutr 1992; 122: 1792–1801. Medline
- 15Kaplan LA, Lau JM, Stein EA. Carotenoid composition, concentrations, and relationships in various human organs. Clin Physiol Biochem 1990; 8: 1–10.
- 16Clinton SK, Emenhiser C, Schwartz SJ, Bostick DG, Williams AW, Moore BJ, Erdman JW Jr. ci-strans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 1996; 5: 823–833. Medline
- 17Key T. Risk factors for prostate cancer. Cancer Surv 1995; 23: 63–77. Medline
- 18Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12: 241–253. Medline
- 19MacLean HE, Choi WT, Rekaris G, Warne GL, Zajac JD. Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy). J Clin Endocrinol Metab 1995; 80: 508–516. Medline
- 20Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 1995; 4: 523–527. Medline
- 21Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937–1940. Medline
- 22Coetzee GA, Ross RK. Re: prostate cancer and the androgen receptor. J Natl Cancer Inst 1994; 86: 872–873. Medline
- 23Woolf CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960; 13: 739–744.
10.1002/1097-0142(196007/08)13:4<739::AID-CNCR2820130414>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 24Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, Henderson BE. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995; 1: 827–829. Medline
- 25Narod SA, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu R, Labrie F. The impact of family history on early detection of prostate cancer. Nat Med 1995; 1: 99–101. Medline
- 26Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337–347. Medline
- 27Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwartz AG, Swanson GM, Silverman DT, Brown LM, Hoover RN, et al. Prostate cancer in U.S. blacks and whites with a family history of cancer. Int J Cancer 1995; 60: 361–364. Medline
- 28Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, Teh CZ, Stamey T. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995; 14: 732–740.
- 29Mostofi FK. Problems of grading carcinoma of the prostate. Semin Oncol 1976; 3: 161–169. Medline
- 30Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975; 2: 105–124. Medline
- 31Steele R, Lees RE, Kraus AS, Rao C. Sexual factors in the epidemiology of cancer of the prostate. J Chronic Dis 1971; 24: 29–37. Medline
- 32Grönberg H, Damber L, Damber JE. Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. J Urol 1996; 155: 969–974. Medline
- 33Rooney C, Beral V, Maconchie N, Fraser P, Davies G. Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority. Br Med J [Clin Res]; 1993; 307: 1391–1397.
- 34Hsing AW, McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr. Tobacco use and prostate cancer: 26 year follow-up of US veterans. Am J Epidemiol 1991; 133: 437–444. Medline
- 35 International Agency for Research on Cancer (IARC). In: DM Parkin, GS Muir, SL Whelan, et al., editors. Cancer incidence in five continents. IARC Scientific Publication no. 120. Lyon: IARC; 1992.
- 36Wiklund K, Dich J, Holm LE, Eklund G. Risk of cancer in pesticide applicators in Swedish agriculture. Br J Ind Med 1989; 46: 809–814. Medline
- 37Makela SI, Pylkkamen LH, Santti RS, Adlercreutz H. Dietary soybean may be antiestrogenic in male mice. J Nutr 1995; 125: 437–445. Medline
- 38Zhang JX, Hallmans G, Landstrom M, Bergh A, Damber JE, Aman P, Adlercreutz H. Soy and rye diets inhibit the development of Dunning R3327 prostatic adenocarcinoma in rats. Cancer Lett 1997; 114: 313–314. Medline
- 39Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 1995; 4: 655–659. Medline
- 40Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998; 7: 385–390. Medline
- 41Fair WR, Fleshner NE, Heston W. Cancer of the prostate: a nutritional disease? Urology 1997; 50: 840–848. Medline
- 42Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40: 43–68. Medline
- 43Jackson MA, Ahluwalia BS, Herson J, Heshmat MY, Jackson AG, Jones GW, Kapoor SK, Kennedy J, Kovi J, Lucas AO, Nkposong EO, Olisa E, Williams AO. Characterization of prostatic carcinoma among blacks: a continuation report. Cancer Treat Rep 1977; 61: 167–172. Medline
- 44Zumoff B, Levin J, Strain GW, Rosenfeld RS, O'Connor J, Freed SZ, Kream J, Whitmore WS, Fukushima DK, Hellman L. Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a “two-disease” theory. Prostate 1982; 3: 579–588. Medline
- 45Harper ME, Peeling WB, Cowley T, Brownsey BG, Phillips ME, Groom G, Fahmy DR, Griffiths K. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol (Copenh); 1976; 81: 409–426.
- 46Habib FK, Lee IR, Stich SR, Smith PH. Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. J Endocrinol 1976; 71: 99–107. Medline
- 47Krain LS. Some epidemiologic variables in prostatic carcinoma in California. Prev Med 1974; 3: 154–159. Medline
- 48Schuman LM, Mandel J, Blackard C, Bauer H, Scarlett J, McHugh R. Epidemiologic study of prostatic cancer: preliminary report. Cancer Treat Rep 1977; 61: 181–186. Medline
- 49Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987; 47: 21–25. Medline
- 50Abe M, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T. Differentiation of mouse myeloid leukemia cells induced by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981; 78: 4990–4994. Medline
- 51Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH. A case-control study of prostatic cancer with reference to dietary habits. Prostate 1988; 12: 179–190. Medline
